Standard

Drug Candidate, CQ-001 (cannabidiol “CBD” + IP system), also demonstrated considerably diminished seizures at better doses, with fewer CBD, in comparison to typical CBD. TORONTO, ON / ACCESSWIRE / December 8, 2022 / CANAQUEST Clinical CORP (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a scientific-phase daily life sciences company focused on […]